Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 207523101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Panacea Innovation Ltd
13D/A
|
25.1% |
7/21/2025
Event 7/21/2025
|
||
| Panacea Innovation Limited | 25.1% | |||
| Panacea Venture Healthcare Fund II, L.P. | 25.1% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 25.1% | |||
| James Huang | 25.1% | |||
|
BioFortune Inc
13G
|
9.6% |
4/14/2026
Event 4/14/2026
|
||
| BioFortune Inc | 9.5% | |||
| Wubin Pan | 9.6% | |||
|
Ikarian Capital, LLC
13G/A
|
6.9% |
8/14/2026
Event 6/30/2026
|
||
| Ikarian Capital, LLC | 6.9% | |||
| Neil Shahrestani | 6.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
| Wei Zheng 13G/A | 4.0% |
8/14/2026
Event 6/30/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 1 | 42.3 k | $101 k |
| 2026 Q1 | 1 | 1.25 k | $3.27 k |
| 2025 Q4 | 1 | 1.29 k | $3.63 k |
| 2025 Q3 | 1 | 1.58 k | $2.39 k |
| 2025 Q2 | 19 | 2.49 M | $2.44 M |
| 2025 Q1 | 14 | 2.83 M | $1.56 M |
| 2024 Q4 | 16 | 3.18 M | $4.37 M |
| 2024 Q3 | 13 | 2.94 M | $4.23 M |
| 2024 Q2 | 16 | 2.98 M | $4.53 M |
| 2024 Q1 | 15 | 3.95 M | $6.87 M |
| 2023 Q4 | 17 | 7.12 M | $8.40 M |
| 2023 Q3 | 15 | 10.1 M | $8.22 M |
| 2023 Q2 | 17 | 10.4 M | $11.7 M |
| 2023 Q1 | 17 | 10.9 M | $10.9 M |
| 2022 Q4 | 21 | 11.1 M | $9.60 M |
| 2022 Q3 | 26 | 12.7 M | $16.4 M |
| 2022 Q2 | 30 | 15.0 M | $13.0 M |
| 2022 Q1 | 30 | 17.7 M | $53.4 M |
| 2021 Q4 | 33 | 17.0 M | $87.5 M |
| 2021 Q3 | 21 | 19.4 M | $467 M |
| 2021 Q2 | 17 | 19.1 M | $372 M |
| 2021 Q1 | 27 | 15.4 M | $285 M |